Spatial Analysis of T-cell Subsets in Lungs of COVID-19 Patients
Many studies have been performed in severe COVID-19 on immune cells in the circulation and on cells obtained by bronchoalveolar lavage. Most studies have tended to provide relative information rather than a quantitative view, and it is a combination of approaches by various groups that is helping the field build a picture of the mechanisms that drive severe lung disease. Approaches employed to date have not revealed information on lung parenchymal T cell subsets in severe COVID-19.
Therefore, we sought to examine early and late T cell subset alterations in the lungs and draining lymph nodes in severe COVID-19 using a rapid autopsy protocol and quantitative imaging approaches. Here, we have established that cytotoxic CD4+ T cells (CD4 + CTLs) increase in the lungs, draining lymph nodes and blood as COVID-19 progresses. CD4 + CTLs are prominently expanded in the lung parenchyma in severe COVID-19. In contrast CD8+ T cells are not prominent, exhibit increased PD-1 expression, and no obvious increase is seen in the number of Granzyme B+ CD8+ T cells in the lung parenchyma in severe COVID-19. Based on quantitative evidence for re-activation in the lung milieu, CD4 + CTLs may be as likely to drive viral clearance as CD8+ T cells and may also be contributors to lung inflammation and eventually to fibrosis in severe COVID-19.
When hospitalized patients with acute COVID-19 were traced back to establish whether they had a previous mRNA vaccine course in the previous 3 to 6 months or had been naturally infected, the Odds Ratio supporting a protective effect of vaccination over natural infection ranged from 5 to 7 depending on the vaccine taken. However, when patients were segregated by age in those 64 and older the Odds Ratio favoring prior mRNA vaccination over natural infection rose to 19.5.
Please, to access the full article visit Science Direct